Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

ABSTRACT

By November 2016, a total of 278 patients had completed the original randomized trials, and 264 (95%) enrolled in this open-label extension. Median treatment duration was 274 days (range 1-512) with a mean modal dose of 21 mg/kg/d, and patients received a median of 3 concomitant antiepileptic medications. Adverse events (AEs) occurred in 93.2% of patients and were mostly mild (36.7%) or moderate (39.0%). Commonly reported AEs were diarrhea (34.5%), pyrexia (27.3%), decreased appetite (25.4%), and somnolence (24.6%). Seventeen patients (6.4%) discontinued due to AEs. Twenty-two of the 128 patients from GWPCARE1 (17.2%), all taking valproic acid, had liver transaminase elevations ≥3 times the upper limit of normal. In patients from GWPCARE1 Part B, the median reduction from baseline in monthly seizure frequency assessed in 12-week periods up to week 48 ranged from 38% to 44% for convulsive seizures and 39% to 51% for total seizures. After 48 weeks of treatment, 85% of patients/caregivers reported improvement in the patient’s overall condition on the Subject/Caregiver Global Impression of Change scale.

SIGNIFICANCE:

This trial shows that long-term CBD treatment had an acceptable safety profile and led to sustained, clinically meaningful reductions in seizure frequency in patients with treatment-resistant DS.

SOURCE
https://www.ncbi.nlm.nih.gov/pubmed/30582156

AUTHORS
1-NYU Comprehensive Epilepsy Center, New York, New York.
2-Necker Hospital for Sick Children, Imagine Institute, Paris, France.
3-Nicklaus Children’s Hospital, Miami, Florida.
4-Ann and Robert H. Lurie Children’s Hospital, Chicago, Illinois.
5-Medical Center Pleiades, Krakow, Poland.
6-GW Research Ltd, Cambridge, UK.

Leave a Reply

Scroll to Top
{"cart_token":"","hash":"","cart_data":""}